EX-10.17 4 s100412_ex10-17.htm EX-10.17 JOINT RESEARCH AND DEVELOPMENT AGREEMENT Between THE JOHNS HOPKINS UNIVERSITY APPLIED PHYSICS LABORATORY AND SECOND SIGHT MEDICAL PRODUCTS, INC.Joint Research and Development Agreement • May 5th, 2020 • Maryland
This Joint Research and Development Agreement (“Agreement”) is made and entered into by and between The Johns Hopkins University Applied Physics Laboratory LLC (“JHU/APL”), and Second Sight Medical Products, Inc. (“Company”) hereinafter collectively referred to as the Parties.
EX-10.17 11 s100332_ex10-17.htm EX-10.17 JOINT RESEARCH AND DEVELOPMENT AGREEMENT Between THE JOHNS HOPKINS UNIVERSITY APPLIED PHYSICS LABORATORY AND SECOND SIGHT MEDICAL PRODUCTS, INC.Joint Research and Development Agreement • May 5th, 2020 • Maryland
This Joint Research and Development Agreement (“Agreement”) is made and entered into by and between The Johns Hopkins University Applied Physics Laboratory LLC (“JHU/APL”), and Second Sight Medical Products, Inc. (“Company”) hereinafter collectively referred to as the Parties.
JOINT RESEARCH AND DEVELOPMENT AGREEMENT BETWEEN UNIVERSITI SAINS MALAYSIA AND ABC SDN BHD IN RELATION TO THE DEVELOPMENT OF ……………..Joint Research and Development Agreement • September 8th, 2020
JOINT RESEARCH AND DEVELOPMENT AGREEMENT THIS JOINT RESEARCH AND DEVELOPMENT AGREEMENT is made on the ___________ day of _____________ 20 (hereinafter referred to as “Agreement”);
Exhibit 10.3 AGREEMENT BETWEEN COLTEC, INC. AND REGI U.S., INC. MADE AS OF OCTOBER 1, 2000. This Agreement is made as of October 1, 2000 (the "Effective Date"), by and between COLTEC, INC. (hereinafter referred to as "ColTec") an Indiana corporation...Joint Research and Development Agreement • August 13th, 2001 • Regi U S Inc • Engines & turbines • Indiana
CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. AGREEMENT OF JOINT RESEARCH AND DEVELOPMENTJoint Research and Development Agreement • May 6th, 2021 • Yubo International Biotech LTD • Electromedical & electrotherapeutic apparatus
Party A is a high-tech R&D center in the biomedicine field, which owns numerous core patent technologies and GMP standard laboratory environment. Its expert team has participated in many national major renewable medical subject and special projects.
FIRST AMENDMENT to an Agreement on joint research and development collaborationJoint Research and Development Agreement • February 22nd, 2023
This AMENDMENT to an Agreement on joint research and development collaboration (“Amendment”) is executed to be effective according to Article 4., by and between
Joint Research and Development Agreement on "Human (Allogeneic) Subcutaneous Adipose Tissue-Derived Mesenchymal Stem Cell Sheet (PAL-222) for Patients with Myopic Chorioretinal AtrophyJoint Research and Development Agreement • July 26th, 2023
PharmaBio Corporation (Headquarter: Nagoya, Aichi; President and CEO: Hitoshi Kusano; hereinafter "PharmaBio") and A2 Healthcare Corporation (Headquarter: Bunkyo-ku, Tokyo; President and CEO: Hitoshi Kamiya; hereinafter "A2") have entered into a joint research and development agreement dated July 14, 2023, on "human (allogeneic) subcutaneous adipose tissue-derived mesenchymal stem cell sheet (PAL-222 (*1)) for the treatment of myopic chorioretinal atrophy (hereinafter "this disease")".
ContractJoint Research and Development Agreement • May 14th, 2016
[WARNING - This sample agreement is only one possible example and is for reference purposes only. It may not meet the needs of specific transactions, and no recommendation is made as to the content of any of the clauses contained herein. Please consider the content of the individual clauses contained herein by also referring to the content of the main text of the Report. You should consult a qualified attorney for your specific needs. Neither the Japan External Trade Organization (JETRO) nor the parties involved in the preparation of this sample agreement assume any responsibility or liability for any use hereof.]
NOVONIX and LG Energy Solution Enter into a JDA for Artificial Graphite Anode Material and a US$30 Million Investment AgreementJoint Research and Development Agreement • June 6th, 2023
NOVONIX and LGES to jointly work toward developing artificial graphite anode material for lithium-ion batteries pursuant to a Joint Research and Development Agreement (“JDA”)
CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. AGREEMENT OF JOINT RESEARCH AND DEVELOPMENTJoint Research and Development Agreement • January 14th, 2021 • Yubo International Biotech LTD • Electromedical & electrotherapeutic apparatus
Party A is a high-tech R&D center in the biomedicine field, which owns numerous core patent technologies and GMP standard laboratory environment. Its expert team has participated in many national major renewable medical subject and special projects.
Joint Research And Development AgreementJoint Research and Development Agreement • November 20th, 2021
ATaesotleofturol pSitcaGnlreeytcshoemnerteimaleisseidn,tehriessVt ehritseNbrialottaeinvtaerrievdeliynsancodrdroadcekderhsasroshilnyv.idPihoyussilcyo! chemical and bluish Hudson processions some dipody so metrically!
ContractJoint Research and Development Agreement • May 14th, 2016
[WARNING - This sample agreement is only one possible example and is for reference purposes only. It may not meet the needs of specific transactions, and no recommendation is made as to the content of any of the clauses contained herein. Please consider the content of the individual clauses contained herein by also referring to the content of the main text of the Report. You should consult a qualified attorney for your specific needs. Neither the Japan External Trade Organization (JETRO) nor the parties involved in the preparation of this sample agreement assume any responsibility or liability for any use hereof.]
Exhibit 10.17 JOINT RESEARCH AND DEVELOPMENT AGREEMENT Party A: Shandong Shengda Technology Co., Ltd Party B: Qingdao University of Science and Technology In line with the principle of reciprocity and mutual benefit and the operational mechanism of...Joint Research and Development Agreement • November 16th, 2006 • Zeolite Exploration Co • Mining & quarrying of nonmetallic minerals (no fuels)
ContractJoint Research and Development Agreement • December 11th, 2019
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
Agreement Between the Union of Soviet Socialist Republics and the People's Republic of China on Joint Research Operations to Determine the Natural Resources of the Amur River Basin and the Prospects for Development of its Productive Potentialities and...Joint Research and Development Agreement • January 18th, 2008
Considering the interest of both Parties in investigating the prospects for developing the productive potentialities of the Amur River basin and in the multi-purpose exploitation thereof,
ADDENDUM TO JOINT RESEARCH AND DEVELOPMENT AGREEMENT (the “Agreement”) By and Between CELLSEED INC. (“CELLSEED”) And EMMAUS MEDICAL INC. (“EMMAUS”)Joint Research and Development Agreement • October 6th, 2011 • Emmaus Life Sciences, Inc. • Blank checks
NOW, THEREFORE, in consideration of the mutual promises and undertakings set forth herein, and intending to be legally bound hereby, CELLSEED and EMMAUS do hereby agree and acknowledge as follows:
Joint Research and Development Agreement on Next-Generation Lithium-ion Battery MaterialJoint Research and Development Agreement • June 19th, 2018
Toshiba Infrastructure Systems & Solutions Corporation (Representative Director: Shinichiro Akiba; Head Office: Kawasaki-shi, Kanagawa; “Toshiba”), an operating company of Toshiba Corporation, Sojitz Corporation (Representative Director: Masayoshi Fujimoto; Chiyoda-ku, Tokyo; “Sojitz”), and Companhia Brasileira de Metalurgia e Mineração (Representative Director: Eduardo Ribeiro; São Paulo, Brazil; “CBMM”), have concluded a joint agreement on the development of anode material for lithium-ion batteries using Niobium Titanium Oxide (NTO). The three companies will cooperate in the development of a next generation lithium-ion battery material characterized by its high-energy density and ultra-rapid recharging capability required for automotive applications.
ContractJoint Research and Development Agreement • April 10th, 2023
Joint research and development agreement with Emulsion Flow Technologies Ltd. for Rare Metal Recycling in Lithium-Ion Batteries
Joint Research and Development AgreementJoint Research and Development Agreement • May 4th, 2011 • Emmaus Holdings, Inc. • Blank checks • New York
WHEREAS, EMMAUS has conducted research in the areas of regenerative medicine to develop certain products. From this regenerative medicine research initiative, EMMAUS is interested in assessing the products which have been or will be developed by CELLSEED, either alone or jointly with EMMAUS;
Kyoto University and Sumitomo Chemical to Start Joint R&D of Solid-Type Batteries for Practical ImplementationJoint Research and Development Agreement • March 16th, 2020
Kyoto University and Sumitomo Chemical Co., Ltd., agreed to jointly develop materials and component technologies that can lead to the practical implementation of solid-type batteries, which have drawn attention as a next-generation rechargeable battery technology. Based on this agreement, Professor Takeshi Abe of the Graduate School of Engineering and Faculty of Engineering at Kyoto University, along with his colleagues, with the support of Sumitomo Chemical, will hold a course focused on joint research between industry and academia. The course will be allocated laboratory-scale manufacturing facilities and battery performance evaluation devices, and will be held on Katsura Campus, Kyoto University, starting April 1, 2020.
ADDENDUM TO JOINT RESEARCH AND DEVELOPMENT AGREEMENT (the “Agreement”) By and Between CELLSEED INC. (“CELLSEED”) And EMMAUS MEDICAL INC. (“EMMAUS”)Joint Research and Development Agreement • May 8th, 2014 • Emmaus Life Sciences, Inc. • Blank checks
NOW, THEREFORE, in consideration of the mutual promises and undertakings set forth herein, and intending to be legally bound hereby, CELLSEED and EMMAUS do hereby agree and acknowledge as follows:
WITNESSETHJoint Research and Development Agreement • February 1st, 1999 • Careside Inc • Surgical & medical instruments & apparatus • Pennsylvania
ContractJoint Research and Development Agreement • May 5th, 2020
EX-10.17 2 v240337_ex10-17.htm EXHIBIT 10.17 MAYOLY SPINDLER / PROTEA JOINT RESEARCH AND DEVELOPMENT AGREEMENT BETWEEN LABORATOIRES MAYOLY SPINDLER SAS, a corporation created and organized under French laws, having its registered office at 6, avenue de l’Europe, 78400 Chatou, France, represented by its President, SCORPIUS SAS, a corporation created and organized under French laws, having its registered office at 55 rue Jouffroy d’Abbans, 75017 Paris, France, itself being represented by its President Mr. Jean-Nicolas VERNIN; hereafter referred to as “LMS”, ON THE ONE HAND, PROTEA EUROPE SAS, a corporation created and organized under French laws having its registered office at 8 Chemin de Maruejols, 30420 Calvisson, France, represented by its President Mr. Daniel Dupret; hereafter referred to as “PROTEA EUROPE”, AND PROTEA Biosciences Inc., a corporation created and organized under the laws of Delaware, whose principal place of business is located at 955 Hartman Run Road, 26507 Morgantow
JOINT RESEARCH AND DEVELOPMENT AGREEMENTJoint Research and Development Agreement • November 14th, 2011 • Protea Biosciences Group, Inc. • Pharmaceutical preparations
LABORATOIRES MAYOLY SPINDLER SAS, a corporation created and organized under French laws, having its registered office at 6, avenue de l’Europe, 78400 Chatou, France, represented by its President, SCORPIUS SAS, a corporation created and organized under French laws, having its registered office at 55 rue Jouffroy d’Abbans, 75017 Paris, France, itself being represented by its President Mr. Jean-Nicolas VERNIN;
JOINT RESEARCH AND DEVELOPMENT AGREEMENTJoint Research and Development Agreement • September 9th, 2011 • Protea Biosciences Inc. • Blank checks
LABORATOIRES MAYOLY SPINDLER SAS, a corporation created and organized under French laws, having its registered office at 6, avenue de l’Europe, 78400 Chatou, France, represented by its President, SCORPIUS SAS, a corporation created and organized under French laws, having its registered office at 55 rue Jouffroy d’Abbans, 75017 Paris, France, itself being represented by its President Mr. Jean-Nicolas VERNIN;
ContractJoint Research and Development Agreement • October 28th, 2013
students on behalf of the students and teaching staff of the Japanese university. In response the stu- dents showed a Japanese folk song and dance, causing a storm of applause.
ContractJoint Research and Development Agreement • March 27th, 2018
Carna Biosciences, Inc. (Head Office: Kobe, Hyogo; President and CEO: Kohichiro Yoshino) (“Carna Biosciences”) and Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Osaka; President and CEO: Masayo Tada) (“Sumitomo Dainippon Pharma”) announced today that, on March 27, 2018, the two companies signed an agreement on joint research with the aim of discovering novel kinase inhibitors for psychiatric and neurological disorders, as well as on the subsequent development and commercialization of such therapeutic agent(s) (hereinafter referred to as the "Agreement").
